Moderna, Inc. (MRNA) Stock Analysis and Metrics

Moderna

NASDAQ: MRNA

$54.05 ▼ -2.97 (-5.21%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap21.46 Bn

P/E-6.72

P/S9.64

Div. Yield0.00

ROIC (Qtr)-0.16

Total Debt (Qtr)590.00 Mn

Revenue Growth (1y) (Qtr)260.19

Add ratio to table…

About

Moderna Inc is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). The company designs mRNA medicines to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit, with the potential to address a broad spectrum of diseases. Its platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the capability to pursue in parallel a robust pipeline of new development candidates. Moderna Inc is developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.

Moderna Inc generates revenue primarily from net product sales of its approved vaccines and other revenue streams including grant revenue, collaboration revenue, licensing and royalty revenue, and stand-ready manufacturing revenue. Its approved products include Spikevax® and mNEXSPIKE® for COVID-19, mRESVIA® for respiratory syncytial virus (RSV), and mCOMBRIAX® for flu plus COVID combination in individuals 50 years of age and older. The company sells its COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations, with U. S. sales primarily through wholesalers and distributors, and to a lesser extent directly to retailers and healthcare providers.

The company operates through the following segments: infectious disease vaccines, oncology therapeutics, and rare disease therapeutics.

• Infectious disease vaccines: This segment focuses on the development and commercialization of mRNA-based vaccines for preventive infectious diseases. It includes approved products such as Spikevax®, mNEXSPIKE®, mRESVIA®, and mCOMBRIAX®. The segment also encompasses a diverse pipeline of vaccine candidates including seasonal flu vaccine (mRNA-1010), norovirus vaccine (mRNA-1403), and others targeting CMV, EBV, HIV, and hMPV.

• Oncology therapeutics: This segment is dedicated to creating mRNA-based therapeutics for cancer treatment. Key programs include intismeran autogene (mRNA-4157) in collaboration with Merck, which is being evaluated in multiple tumor types such as melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and renal cell carcinoma. Another wholly-owned investigational cancer antigen therapy, mRNA-4359, is being studied in first-line metastatic melanoma, second-line+ metastatic melanoma, and first-line metastatic NSCLC.

• Rare disease therapeutics: This segment targets rare metabolic diseases with significant unmet medical need using mRNA therapeutics. The lead candidate is mRNA-3927 for propionic acidemia (PA), which is currently in a registrational study with target enrollment reached and potential data expected in 2026. The segment also includes mRNA-3705 for methylmalonic acidemia (MMA), for which a pivotal trial decision is being deferred until PA data readout.

Moderna Inc holds a leading position in the mRNA therapeutics industry, having pioneered the development and commercialization of mRNA-based medicines. Its competitive advantages stem from its integrated platform encompassing mRNA science, delivery technology, and manufacturing capabilities that enable rapid clinical and commercial production at scale. The company faces competition from other biotechnology and pharmaceutical firms developing mRNA and vaccine technologies, but its early mover advantage, broad intellectual property portfolio, and diversified pipeline across infectious diseases, oncology, and rare diseases differentiate it in the market.

Moderna Inc serves a diverse customer base including commercial wholesalers and distributors, retailers, healthcare providers, foreign governments, and international organizations. In the United States, its COVID and RSV vaccines are sold primarily through wholesalers and distributors, with additional sales to retailers and healthcare providers. Internationally, the company supplies vaccines to government entities under long-term strategic partnerships, supporting pandemic preparedness and public health initiatives.

Investment Thesis

▲ Bull case

Moderna's mRNA-1010 flu vaccine trial demonstrated 26.6% superior efficacy over standard-dose GSK flu shots in a late-stage international study of over 40,000 adults aged 50+, with the FDA accepting an amended application after initial rejection and scheduling an advisory committee meeting for June 18, positioning the vaccine for a potential August 5 PDUFA decision that could unlock the first mRNA-based seasonal flu shot in the U.S. market, addressing a significant unmet need given that conventional flu vaccines show variable effectiveness and Moderna's platform offers faster adaptation to circulating strains, which could drive strong uptake particularly among older adults and establish a foundation for annual revenue streams from strain updates similar to its COVID vaccine franchise.
The European Commission's approval of Moderna's mRNA flu-COVID combination vaccine (mCOMBRIAX) for adults 50+ in April creates a near-term catalyst for 2027 EU launch, with Stephen Hoge explicitly stating the company expects to gain "a very large share of that $1.8 billion to $2 billion respiratory vaccines market" in Europe, leveraging the product's value proposition of single-shot convenience reducing healthcare system burden and patient preference, while pricing and reimbursement discussions are already underway in key markets like France, indicating strong payer engagement that could accelerate adoption post-approval and drive meaningful revenue contribution starting in 2027 as the company expands beyond its current four approved products.
Moderna's personalized cancer vaccine Intismeran, in combination with Merck's Keytruda, showed 59% reduction in risk of cancer spread after five years of follow-up in a mid-stage melanoma trial, with overall survival of 92.2% versus 71.3% for Keytruda alone, and Stephen Hoge highlighted the therapy's remarkable safety profile with no significant increase in serious Grade 3 events despite IO-IO benefit, supporting the ongoing Phase III monotherapy trial in high-risk Stage 1 non-small cell lung cancer where standard of care is surgery and watchful waiting, offering a unique opportunity to intervene early in a large patient population benefiting from increased Stage 1 diagnoses through chest x-ray screening, which could establish Intismeran as a curative vaccine-like therapy with broad applicability across early-stage oncology indications.
The undisclosed pre-clinical hantavirus vaccine partnership with the U.S. Army and Korea University College of Medicine, initiated in 2024 and gaining relevance amid hantavirus outbreak concerns on cruises, represents a hidden pandemic preparedness catalyst that management did not emphasize during the earnings call, positioning Moderna to leverage its mRNA platform for rapid response to emerging threats similar to its COVID-19 success, with CEPI's recent $60 million grant for Ebola Bundibugyo vaccine development further validating the company's role in global health security and potentially opening non-dilutive funding pathways for other high-consequence pathogens beyond the current pipeline.
Moderna's norovirus vaccine Phase III trial is fully enrolled in its second Northern Hemisphere season with case accrual ongoing, and Stephen Hoge noted the company expects data from this study in 2026, addressing a significant unmet need as no approved norovirus vaccine exists despite high societal and medical costs from dehydration and exacerbation of underlying diseases in high-risk populations over 75, with the company indicating statistical significance as the success bar but aiming for vaccine efficacy north of 50%, which could unlock a multi-billion dollar market given norovirus's high morbidity and lack of current prevention options, particularly as the vaccine progresses through late-stage development without major safety concerns highlighted in prior trials.

Moderna's mRNA-1010 flu vaccine trial demonstrated 26.6% superior efficacy over standard-dose GSK flu shots in a late-stage international study of over 40,000 adults aged 50+, with the FDA accepting an amended application after initial rejection and scheduling an advisory committee meeting for June 18, positioning the vaccine for a potential August 5 PDUFA decision that could unlock the first mRNA-based seasonal flu shot in the U.S. market, addressing a significant unmet need given that conventional flu vaccines show variable effectiveness and Moderna's platform offers faster adaptation to circulating strains, which could drive strong uptake particularly among older adults and establish a foundation for annual revenue streams from strain updates similar to its COVID vaccine franchise.
The European Commission's approval of Moderna's mRNA flu-COVID combination vaccine (mCOMBRIAX) for adults 50+ in April creates a near-term catalyst for 2027 EU launch, with Stephen Hoge explicitly stating the company expects to gain "a very large share of that $1.8 billion to $2 billion respiratory vaccines market" in Europe, leveraging the product's value proposition of single-shot convenience reducing healthcare system burden and patient preference, while pricing and reimbursement discussions are already underway in key markets like France, indicating strong payer engagement that could accelerate adoption post-approval and drive meaningful revenue contribution starting in 2027 as the company expands beyond its current four approved products.
Moderna's personalized cancer vaccine Intismeran, in combination with Merck's Keytruda, showed 59% reduction in risk of cancer spread after five years of follow-up in a mid-stage melanoma trial, with overall survival of 92.2% versus 71.3% for Keytruda alone, and Stephen Hoge highlighted the therapy's remarkable safety profile with no significant increase in serious Grade 3 events despite IO-IO benefit, supporting the ongoing Phase III monotherapy trial in high-risk Stage 1 non-small cell lung cancer where standard of care is surgery and watchful waiting, offering a unique opportunity to intervene early in a large patient population benefiting from increased Stage 1 diagnoses through chest x-ray screening, which could establish Intismeran as a curative vaccine-like therapy with broad applicability across early-stage oncology indications.
The undisclosed pre-clinical hantavirus vaccine partnership with the U.S. Army and Korea University College of Medicine, initiated in 2024 and gaining relevance amid hantavirus outbreak concerns on cruises, represents a hidden pandemic preparedness catalyst that management did not emphasize during the earnings call, positioning Moderna to leverage its mRNA platform for rapid response to emerging threats similar to its COVID-19 success, with CEPI's recent $60 million grant for Ebola Bundibugyo vaccine development further validating the company's role in global health security and potentially opening non-dilutive funding pathways for other high-consequence pathogens beyond the current pipeline.
Moderna's norovirus vaccine Phase III trial is fully enrolled in its second Northern Hemisphere season with case accrual ongoing, and Stephen Hoge noted the company expects data from this study in 2026, addressing a significant unmet need as no approved norovirus vaccine exists despite high societal and medical costs from dehydration and exacerbation of underlying diseases in high-risk populations over 75, with the company indicating statistical significance as the success bar but aiming for vaccine efficacy north of 50%, which could unlock a multi-billion dollar market given norovirus's high morbidity and lack of current prevention options, particularly as the vaccine progresses through late-stage development without major safety concerns highlighted in prior trials.

▼ Bear case

Moderna's Q1 2026 revenue growth was driven almost entirely by international strategic partnership deliveries (80% of $400 million revenue), with U.S. sales contributing only 20%, and James Mock explicitly stated the company expects second-quarter revenue between $50 million and $100 million evenly split between U.S. and international markets, which is below analysts' estimate of $130.6 million, indicating a significant pull-forward of international orders that leaves minimal organic U.S. growth momentum for the remainder of 2026 despite the reiterated up to 10% full-year revenue growth target, suggesting the guidance relies heavily on timing of partnership shipments rather than sustainable commercial traction in core markets.
The litigation settlement with [indiscernible] continues to pose substantial financial risk, as James Mock revealed Moderna will make a $950 million lump sum payment in Q3 2026 (with $878 million already recognized in Q1 cost of sales) and agreed to an additional potential payment of up to $1.3 billion if the Federal Circuit finds liability under Section 1498, with Luca Issi noting the final ruling could be late 2027 or 2028, creating a multi-year overhang where Moderna has not reserved any capital for this contingency despite acknowledging the possibility, and the company's confidence in prevailing is based solely on internal legal assessment without external validation, leaving investors exposed to a binary outcome that could severely impact cash reserves projected to decline to $4.5–$5.0 billion by end-2026.
Moderna's R&D pipeline progression shows concerning delays and limited near-term catalysts, as Stephen Hoge admitted the company cannot guide on timing for interim data from RCC and muscle invasive bladder cancer Phase II studies due to their event-driven nature, while the Intismeran adjuvant melanoma Phase III interim analysis lacks a built-in futility assessment, meaning the trial could continue accruing events for years without clear success criteria, and the norovirus vaccine, though fully enrolled, faces uncertainty in demonstrating meaningful efficacy against a disease with no standard of care, where even statistical significance may not translate to commercial adoption without clear superiority over supportive care, reducing near-term probability of positive data readouts that could drive investor confidence beyond the already-anticipated 2026 milestones.
The company's dependence on mRNA technology faces growing political and regulatory headwinds, as Health Secretary Robert F. Kennedy Jr.'s prominent criticism of mRNA vaccines—including canceling hundreds of millions in research funding and making unsupported claims—has created uncertainty over U.S. immunization policy, with Moderna itself acknowledging U.S. immunization policy has taken a sharp turn under Kennedy, and while Stephen Hoge stated the flu vaccine review continues independently of senior leadership interactions, the broader environment remains hostile to mRNA platforms, potentially affecting future vaccine recommendations, reimbursement policies, and public acceptance, which could undermine Moderna's core assumption of stable U.S. COVID market recovery and limit adoption of new mRNA products despite clinical efficacy.
Moderna's commercial expansion strategy for its newly approved EU products relies on lengthy market access and pricing negotiations, as Stephen Hoge explicitly noted that securing reimbursement in Europe "takes a couple of years as a process" and significant uplift from mCOMBRIAX may not materialize until 2028, with similar delays expected for mRNA-1010 flu vaccine in the U.S. given the FDA's requirement for an additional study in older adults post-approval, meaning the company's near-term revenue growth will remain dependent on volatile COVID vaccine shipments and partnership deliveries rather than sustainable uptake of new vaccines, and the oncology pipeline, while promising, remains years from potential approval with Intismeran monotherapy lung cancer data not expected until beyond 2026, leaving a gap between current cash burn and tangible near-term revenue catalysts.

Moderna's Q1 2026 revenue growth was driven almost entirely by international strategic partnership deliveries (80% of $400 million revenue), with U.S. sales contributing only 20%, and James Mock explicitly stated the company expects second-quarter revenue between $50 million and $100 million evenly split between U.S. and international markets, which is below analysts' estimate of $130.6 million, indicating a significant pull-forward of international orders that leaves minimal organic U.S. growth momentum for the remainder of 2026 despite the reiterated up to 10% full-year revenue growth target, suggesting the guidance relies heavily on timing of partnership shipments rather than sustainable commercial traction in core markets.
The litigation settlement with [indiscernible] continues to pose substantial financial risk, as James Mock revealed Moderna will make a $950 million lump sum payment in Q3 2026 (with $878 million already recognized in Q1 cost of sales) and agreed to an additional potential payment of up to $1.3 billion if the Federal Circuit finds liability under Section 1498, with Luca Issi noting the final ruling could be late 2027 or 2028, creating a multi-year overhang where Moderna has not reserved any capital for this contingency despite acknowledging the possibility, and the company's confidence in prevailing is based solely on internal legal assessment without external validation, leaving investors exposed to a binary outcome that could severely impact cash reserves projected to decline to $4.5–$5.0 billion by end-2026.
Moderna's R&D pipeline progression shows concerning delays and limited near-term catalysts, as Stephen Hoge admitted the company cannot guide on timing for interim data from RCC and muscle invasive bladder cancer Phase II studies due to their event-driven nature, while the Intismeran adjuvant melanoma Phase III interim analysis lacks a built-in futility assessment, meaning the trial could continue accruing events for years without clear success criteria, and the norovirus vaccine, though fully enrolled, faces uncertainty in demonstrating meaningful efficacy against a disease with no standard of care, where even statistical significance may not translate to commercial adoption without clear superiority over supportive care, reducing near-term probability of positive data readouts that could drive investor confidence beyond the already-anticipated 2026 milestones.
The company's dependence on mRNA technology faces growing political and regulatory headwinds, as Health Secretary Robert F. Kennedy Jr.'s prominent criticism of mRNA vaccines—including canceling hundreds of millions in research funding and making unsupported claims—has created uncertainty over U.S. immunization policy, with Moderna itself acknowledging U.S. immunization policy has taken a sharp turn under Kennedy, and while Stephen Hoge stated the flu vaccine review continues independently of senior leadership interactions, the broader environment remains hostile to mRNA platforms, potentially affecting future vaccine recommendations, reimbursement policies, and public acceptance, which could undermine Moderna's core assumption of stable U.S. COVID market recovery and limit adoption of new mRNA products despite clinical efficacy.
Moderna's commercial expansion strategy for its newly approved EU products relies on lengthy market access and pricing negotiations, as Stephen Hoge explicitly noted that securing reimbursement in Europe "takes a couple of years as a process" and significant uplift from mCOMBRIAX may not materialize until 2028, with similar delays expected for mRNA-1010 flu vaccine in the U.S. given the FDA's requirement for an additional study in older adults post-approval, meaning the company's near-term revenue growth will remain dependent on volatile COVID vaccine shipments and partnership deliveries rather than sustainable uptake of new vaccines, and the oncology pipeline, while promising, remains years from potential approval with Intismeran monotherapy lung cancer data not expected until beyond 2026, leaving a gap between current cash burn and tangible near-term revenue catalysts.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password